Regulation News: Breaking Regulation News, Comments and Articles. - Page: 2

Findings highlight importance of IL-21 in the development of antiviral vaccines

Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.

Anesthesia Billing Consultants Physician Office Partners, Inc. Help Clients Increase Revenues with Comprehensive Solution

Overland Park, KS, May 24, 2013 --(PR.com)-- Kansas-based anesthesia billing consultants Physician Office Partners, Inc. is now offering a solution that will enable anesthesia services providers to reduce their in-house administrative costs and improve revenues. The company’s solution works to provide a full anesthesia billing cycle that takes charges from the capture stage to the payment s...

Aegon Appoints Global Chief Technology Officer

THE HAGUE, The Netherlands, May 24, 2013 /PRNewswire/ -- Aegon announces the appointment of Aegon Americas COO Brenda Clancy to the new role of Global Chief Technology Officer, effective June 1, 2013. Ms. Clancy will develop and lead Aegon's Group-wide global IT governance framework and enterprise IT strategy. The appointment is an essential step in the Group's long-term strategic commitment to c...

Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013

London, UK (PRWEB) May 24, 2013 Wednesday, 15th May 2013 | 10am BST | 5pm HKT Duration: 60mins Register to access webinar playback: http://bit.ly/10Rt0ZH Ongoing regulatory changes are likely to touch every corner of the financial mark...

Functional Technologies Receives Extension of Creditor Protection Period

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/24/13 -- Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") reports that the court has granted an extension, until June 12, 2013, of the initial creditor protection period reported in the Company's news release of April 25, 2013. About Functional Technologies Corp. Functional Technologies develops and commercializes proprietary,...

Patient Home Monitoring (PHM) Announces An Update On Progress to Improve Gross Margin and Revenue Growth

SAN FRANCISCO, CALIFORNIA -- (Marketwired) -- 05/24/13 -- Patient Home Monitoring (PHM) (TSX VENTURE: PHM), a profitable company focused on in-home management for patients with chronic disease, today announced a number of actions it plans to undertake to increase profitability, improve capital market liquidity and increase shareholder value. PHM has finalized the acquisition of LM Pharmacy Solut...

CMS Issues Proposed Payment Regulation

Computational Study Tracks E. coli Cells' Regulatory Mechanisms

Environment is not the only factor in shaping regulatory patterns - and it might not even be the primary factor, according to a new Rice University study that looks at how cells' protein networks relate to a bacteria's genome. The Rice lab of compute...

Modulating the immune system to combat metastatic cancer

(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors express proteins that can be targeted with therapeu...

Lawmaker would give FDA more oversight of drug compounding

WASHINGTON (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug compounding...

U.S. lawmaker would give FDA more oversight of drug compounding

WASHINGTON, May 23 (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug com...

EMA recommends measures to minimise Dianette’s risks

Benefits of Dianette (cyproterone acetate 2mg, ethinylestradiol 35micrograms) and its generics outweigh the risks, provided that several measures are taken to minimise the risk of thromboembolism, the European Medicines Agency’s Pharmacovigilance...

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladena...

Health Net Selected to Participate in Covered California Health Insurance Exchange

Individuals will be able to enroll in Health Net’s health plans when the new exchange opens for business Health Net of California, Inc., a wholly owned subsidiary of Health Net, Inc. (NYSE: HNT), today announced that it has been selected as a Covered California health plan in the Covered California individual health insurance exchange....

Merck discontinues preladenant for PD

Merck & Co. Inc. (NYSE:MRK) said it no longer plans to submit regulatory applications for preladenant to treat Parkinson's disease after an initial review of data from three double-blind Phase III trials "did not provide evidence of efficacy" for the...

Novo's liraglutide meets obesity endpoints

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said once-daily 3 mg subcutaneous liraglutide met the three co-primary endpoints in the Phase IIIa SCALE Obesity and Pre-diabetes trial to treat obesity. Liraglutide reduced mean body weight from baseline to week...

Less Competition on Health Insurance Exchange Could Lead to Higher Rates Absent Health Insurance Rate Regulation

SANTA MONICA, Calif., May 23, 2013 /PRNewswire-USNewswire/ -- Consumer Watchdog responded today to the news that the state's three largest health insurance companies would continue to dominate the health insurance market in the California health exchange with concerns that patients will continue to pay excessive premiums because of decreased competition.  The group applauded the fact that Cal...

Life Spine® Announces Continuing Offshore and International Growth

Life Spine, a medical device company that markets products for the surgical treatment of spinal disorders, announced today the company is rapidly expanding its footprint outside of the mainland U.S. New customers in Hawaii and Puerto Rico, as well as New Zealand, Brazil, and India have recently begun purchasing products from Life Spine’s broad product po...

Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System

PHILADELPHIA, May 23, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following yesterday's annual stockholders meeting.  Addit...

EU to kick off talks on stronger trade mark system

Next week the European Parliament’s legal affairs committee (JURI) will examine a draft Regulation aimed at streamlining the procedures for obtaining a single trade mark valid throughout the EU. The document, drawn up by the .....

Top 5 Pharmaceutical Company Inoculates Global Operations Against FCPA Violations

Company Expands Global Use of Aravo Solutions Across Business Units to Ensure Best-Practice Due Diligence Processes Aravo Solutions, Inc., the leading provider of cloud-based Supplier Lifecycle Management (SLM) solutions and supplier risk services, announced today that a Fortune 500 Top 5 Pharmaceutical customer has elected to expand its use of Aravo S...

Viewpoints: Sen. Alexander Sees Reflections Of Oliver North In Sebelius' Quest To Raise Funds; Vaccine Scare's Legacy

The Wall Street Journal: Kathleen Sebelius, Meet Oliver North Major news outlets in recent days have reported that U.S. Department of Health and Human Services Secretary Kathleen Sebelius is raising money from the private sector -- including from health care executives -- for use by a private entity that is helping to implement ObamaCare. ... Is Ms. Sebelius raising funds for a private entity and...

J&J plans to submit 10 new drugs for approval by 2017

Johnson & Johnson's pharmaceuticals segment plans to submit 10 new product filings for regulatory approval over the next four years. These products are aimed at addressing serious unmet medical needs, such as Hepatitis C, schizophrenia and influe...

J&J plans filing on more than 10 new drugs by 2017

(Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and polio.

UPDATE 1-J&J plans filing on more than 10 new drugs by 2017

May 23 (Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and polio.